Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, ...

Nuvaxovid is a recombinant protein-based COVID ... Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...